Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 13/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 10/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1030223 | 1.00 | HCRTR2 (0.39) | HCRTR2HCRTR1L3MBTL1TBXA2RAPLNR | |
| SCHEMBL1030224 | 1.00 | HCRTR2 (0.39) | HCRTR2HCRTR1L3MBTL1TBXA2RAPLNR | |
| SCHEMBL9154429 | 0.98 | HCRTR2 (0.38) | HCRTR2HCRTR1L3MBTL1TBXA2RAPLNR | |
| SCHEMBL2936815 | 0.98 | HCRTR2 (0.38) | HCRTR2HCRTR1L3MBTL1TBXA2RAPLNR | |
| Hydrochloric Acid SCHEMBL5195834 | 0.98 | HCRTR2 (0.38) | HCRTR2HCRTR1L3MBTL1TBXA2RAPLNR | |
| SCHEMBL1761274 | 0.98 | HCRTR2 (0.38) | HCRTR2HCRTR1L3MBTL1TBXA2RAPLNR | |
| SCHEMBL1764599 | 0.98 | HCRTR2 (0.38) | HCRTR2HCRTR1L3MBTL1TBXA2RAPLNR | |
| SCHEMBL2936811 | 0.98 | HCRTR2 (0.38) | HCRTR2HCRTR1L3MBTL1TBXA2RAPLNR | |
| Acetic Acid SCHEMBL21617326 | 0.98 | HCRTR2 (0.38) | HCRTR2HCRTR1L3MBTL1TBXA2RAPLNR | |
| SCHEMBL9162631 | 0.98 | HCRTR2 (0.38) | HCRTR2HCRTR1L3MBTL1TBXA2RAPLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124317-A2 | Antibody Drug Conjugates | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| EP-4729059-A2 | THIAZOLO [5,4-B] PYRIDINE MALT-1 INHIBITORS | Abbvie Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4581035-A1 | EXATECAN-DERIVED TOPOISOMERASE-1 INHIBITORS PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20250135026-A1 | Antibody Drug Conjugates | BEIGENE SWITZERLAND GMBH (CH) | 2025-05-01 | — | — | US | disclosed |
| CN-119855821-A | Thiazolo [5,4-b ] pyridine MALT-1 inhibitors | 艾伯维公司 | 2025-04-18 | — | — | CN | disclosed |
| US-20250084099-A1 | THIAZOLO[5,4-B]PYRIDINE MALT-1 INHIBITORS | ABBVIE INC (US) | 2025-03-13 | — | — | US | disclosed |
| EP-4499650-A1 | THIAZOLO [5,4-B] PYRIDINE MALT-1 INHIBITORS | Abbvie Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-118450907-A | Antibody drug conjugates | 百济神州有限公司 | 2024-08-06 | — | — | CN | disclosed |
| US-20240217942-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-12011425-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-5512207-A | Azaaromatic compounds, process for their preparation, and their use in liquid-crystalline mixtures | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-04-30 | — | — | US | disclosed |
| EP-0426253-B1 | Process for the separation of R and S-2,2R1, R2-1,3-dioxolane-4-carboxylic acid | SHELL INT RESEARCH (NL) | 1995-02-22 | — | — | EP | disclosed |
| EP-0580402-A2 | Aminediol protease inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1994-01-26 | — | — | EP | disclosed |
| US-5190867-A | Process for the preparation of R-2,2-R1,R2 -1,3-dioxolane-4-methanol | SHELL INTERNATIONAL PETROLEUM COMPANY, LTD. (GB) | 1993-03-02 | — | — | US | disclosed |
| US-5164519-A | Process for the separation of R and S-2,2-R1,R2 -1,3-dioxolane-4-carboxylic acid | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 1992-11-17 | — | — | US | disclosed |
| EP-0426253-A1 | Process for the separation of R and S-2,2R1, R2-1,3-dioxolane-4-carboxylic acid | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1991-05-08 | — | — | EP | disclosed |
| EP-0244912-B1 | A PROCESS FOR THE PREPARATION OF R AND S-2,2-R1,R2-1,3-DIOXOLANE-4-METHANOL | GIST-BROCADES N.V. (NL) | 1990-06-27 | — | — | EP | disclosed |
| EP-0244912-A1 | A process for the preparation of R and S-2,2-R1,R2-1,3-dioxolane-4-methanol | GIST-BROCADES N.V. (NL) | 1987-11-11 | — | — | EP | disclosed |
| US-4691032-A | DIMETHYL- AND TETRAMETHYL-1,3-DIOXOLANE-4-CARBOXALDEHYDES | HOFFMANN-LA ROCHE INC. (US) | 1987-09-01 | — | — | US | disclosed |
| US-4568491-A | FOR VITAMIN D3 SYNTHESIS | HOFFMANN-LA ROCHE INC. (US) | 1986-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124317-A2 | Antibody Drug Conjugates | SLC3A2, SLC7A1, SLC43A1 | HCRTR2 2569/4885HCRTR1 3241/4885L3MBTL1 1899/4885 |
| US-20250135026-A1 | Antibody Drug Conjugates | CD22, FCGR2A, FCGR3B | HCRTR2 3782/4885HCRTR1 4487/4885L3MBTL1 1812/4885 |
| US-12011425-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | HCRTR2 3283/4885HCRTR1 2151/4885L3MBTL1 2647/4885 |
| US-20250084099-A1 | THIAZOLO[5,4-B]PYRIDINE MALT-1 INHIBITORS | MALT1, PTP4A1, AMY1A | HCRTR2 4773/4885HCRTR1 4206/4885L3MBTL1 1314/4885 |
| US-20240217942-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | HCRTR2 51/4885HCRTR1 28/4885L3MBTL1 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.